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Abstract
Background/Aims—Incidence of cholangiocarcinoma is increasing worldwide, yet remaining
highly aggressive and with poor prognosis. The mechanisms that drive cholangiocyte transition
towards malignant phenotype are obscure. Cholangiocyte benign proliferation is subjected to a self-
limiting mechanism based on the autocrine release of endogenous opioid peptides. Despite the
presence of both, ligands interact with δ opioid receptor (OR), but not with µOR, with the consequent
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inhibition of cell growth. We aimed to verify whether cholangiocarcinoma growth is associated with
failure of opioidergic regulation of growth control.
Methods—We evaluated the effects of OR selective agonists on cholangiocarcinoma cell
proliferation, migration and apoptosis. Intracellular signals were also characterised.
Results—Activation of µOR, but not δOR, increases cholangiocarcinoma cell growth. Such an
effect is mediated by ERK1/2, PI3K and Ca2+–CamKIIα cascades, but not by cAMP/PKA and
PKCα. µOR activation also enhances cholangiocarcinoma cell migration and reduces death by
apoptosis. The anti-apoptotic effect of µOR was PI3K dependent.
Conclusions—Our data indicate that cholangiocarcinoma growth is associated with altered
opioidergic regulation of cholangiocyte biology, thus opening new scenarios for future surveillance
or early diagnostic strategies for cholangiocarcinoma.
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Cholangiocarcinoma; Endogenous opioid peptides; Proliferation; Survival
1. Introduction
Cholangiocarcinoma is the malignancy arising from cholangiocytes, the epithelial cells lining
the biliary tree [1]. Cholangiocarcinoma is a highly aggressive tumour; in particular, its
incidence has been increasing worldwide over the past several decades [2] and it accounts now
for 10–15% of all hepatobiliary malignancies [3].
The etiology of cholangiocarcinoma remains unclear. Several risk factors for the development
of this disease, such as primary sclerosing cholangitis (PSC) or chronic hepatobiliary parasitic
infections, have been identified [3]. However, it is common experience that, at least in Western
countries, the majority of patients affected by cholangiocarcinoma do not show any of the
known factors [3]. In addition, the majority of patients with cholangiocarcinoma have advanced
and inoperable disease at the time of diagnosis and, overall, the 5-year relative survival rate
after diagnosis is less than 10% [4]. Thus, better understanding of the molecular bases of the
failure of the regulation of cholangiocyte proliferation that gives rise to biliary cancer is thought
to be essential for developing novel strategies and therapeutic targets to prevent, diagnose and
cure this fatal neoplasm.
Normal and malignant cholangiocyte growth is regulated by neuropeptides and neuroendocrine
hormones [5,6]. We have recently demonstrated that cholangiocytes are susceptible to the
action of endogenous opioid peptides, by the activation of δOR and µOR [7]. In particular, we
found that the local release of endogenous opioid peptides in the course of chronic cholestasis
is functional to the activation of the δOR, with the consequent inhibition of cholangiocyte
hyperplastic proliferative response to injury [7].
Since endogenous opioid peptides regulate the growth of several malignancies [8–14], we
wanted to verify if they also affect cholangiocarcinoma development. In particular, we aimed
to answer the following questions: (i) do cholangiocarcinoma cells express δOR and µOR? (ii)
What are the effects of OR activation on cholangiocarcinoma cell proliferation? (iii) Which
intracellular events do mediate the OR effects on cholangiocarcinoma cell proliferation? Is OR
activation also responsible for changes in cholangiocarcinoma cell migration (iv) and death by
apoptosis (v)?
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2. Materials and methods
2.1. Cell culture and OR expression
The study was performed in HuH-28, Mz-ChA-1 and TFK-1 cholangiocarcinoma cell lines
[15,16]. Mz-ChA-1 cells, from human gallbladder [15], were a gift from Dr. G. Fitz (University
of Texas Southwestern Medical Center, Dallas, TX); HuH-28, from human intrahepatic bile
duct [16], and TFK-1 cells, from human extrahepatic bile duct [17], were acquired from the
Cancer Cell Repository, Tohoku University, Japan. Cells were maintained in standard
conditions, as previously described [18,19]. Expression of δOR (isoform 1) and µOR (isoform
1) was evaluated by immunoblots in whole cell lysate, as previously described by us and others
[7,20,21]. OR expression was also assessed in a hepatocarcinoma cell line, Alex-0 cells (PRF/
PLC/5), that was a gift from Prof. R. Mazzanti (University of Florence, Italy) [22].
2.2. Effect of OR activation on cholangiocarcinoma cell proliferation
After trypsinization, cells were seeded into 96-well plates (5000 per well) in a final volume of
100 µl medium. To verify if OR activation has potential effects in inhibiting
cholangiocarcinoma cell proliferation, HuH-28, Mz-ChA-1 and TFK-1 were incubated in 10%
FBS medium for 24 h at 37 °C with (i) 0.2% BSA (control) or increasing concentrations of:
(ii) [D-pen2,5]-enkephalin (DPDPE, 1 nmol/L to 1 µmol/L, δOR selective agonist) [7,9]; (iii)
[D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO, 1 nmol/L to 1 µmol/L, µOR selective
agonist) [7,9]. To verify if OR activation has potential effects in stimulating
cholangiocarcinoma cell proliferation, the same experimental approach was performed in cells
kept in a FBS-free medium. Changes in bromodeoxyuridine (BrDU) incorporation were
measured employing the Cell Proliferation ELISA BrDU assay (Roche, Monza, Italy), as
previously described [7]. Changes in cell proliferation were also assayed by immunoblots for
the Proliferating Cell Nuclear Antigen (PCNA) protein expression, as previously reported [7,
23,24].
2.3. Characterization of OR intracellular signalling
HuH-28 cells were incubated in FBS-free medium with (i) 0.2% BSA (control); (ii) DAMGO
for 30 min. Changes in CamKIIα, PKCα, ERK1/2 and AKT phosphorylation were then assayed
by immunoblots, as previously described [7,23]. Changes in cAMP-dependent PKA activity
was measured using the PepTag Assay Protein Kinase Kit, according to the instructions of the
manufacturer, as previously described by us [7,23].
HuH-28 cells were also incubated in the absence or presence of a 30 min pre-incubation with
either Rp-cAMPs (100 µmol/L, a cAMP-dependent PKA inhibitor) [7], PD98059 (50 µmol/
L, a MEK inhibitor) [7,25], wortmannin (100 nmol/L, a PI3K inhibitor) [7], BAPTA/AM (an
intracellular Ca2+ chelator, 5 µmol/L) [7,23], KN62 [10 µmol/L, a Calcium-Calmoduline-
Kinase (CamK) II inhibitor] [7], or Ro-32-0432 (0.5 µmol/L, a Ca2+-dependent PKC inhibitor)
[7]. Changes in cell proliferation were then assayed as described above.
2.4. Effect of OR activation on cholangiocarcinoma cell migration
Changes in cholangiocarcinoma cell migration were assessed by “wound-healing” assay, as
we previously described [18], and by the CytoSelect™ 24-well cell migration assay. Briefly,
30,000 cells/well, after starvation overnight, were seeded in serum-free CMRL1066 and placed
in the upper well insert of a 24-well plate, in absence or presence of DAMGO (100 nmol/L),
and allowed to migrate toward FBS as chemoattractant to the lower well. After 24-h incubation,
cells that migrated through the 8 µm pore membranes, located at the bottom of every well
insert, were first dissociated from membrane, then lysed and detected by patented
Marzioni et al. Page 3
Dig Liver Dis. Author manuscript; available in PMC 2009 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
CyQuantGRDye (Invitrogen, Milan, Italy) in a fluorescence plate reader at 480 nm/520 nm
wavelength.
2.5. Effect of OR activation on cholangiocarcinoma cell survival
After trypsinization, 5000 cells/well were seeded into 96-well plates in a final volume of 50
µl medium. Cell death by apoptosis was induced by incubating HuH-28 in FBS-free medium
for 4 h with glycochenodeoxycholic acid (GCDCA, 400 nmol/L) [26,27], in the absence or
presence of a 30 min pre-incubation with DAMGO.
To define the intracellular pathways that mediate the effect of DAMGO on cholangiocarcinoma
cell survival, the above experiments were also performed in the absence or presence of a 30
min pre-incubation with either, PD98059 (50 µmol/L) [7,25], wortmannin (100 nmol/L) [7]
or KN62 [10 µmol/L, a CamKII inhibitor] [7].
Changes in caspase 3 activation were then measured by the APO-ONE Homogeneous
Caspase-3/7, according to the instruction provided by the vendor.
2.6. Materials
Reagents were purchased from Sigma–Aldrich (Milan, Italy) unless otherwise indicated.
PD98059, Rp-cAMPs, KN62, Ro-32-0432, BAPTA/AM were purchased from Calbiochem
(Milan, Italy). All the antibodies employed for immunoblotting studies were purchased from
Santa Cruz (Milan, Italy), for the exception of the one for β-actin (Sigma–Aldrich, Milan, Italy).
PepTag Assay Protein Kinase A Kit and APO-ONE Homogeneous Caspase-3/7 Assay were
purchased from Promega (Milan, Italy). CytoSelect™ 24-well cell migration assay was
purchased from Cellbiolabs (Heidelberg, Germany).
2.7. Statistical analysis
All data are expressed as mean ± S.E. and expressed as % of basal value, unless differently
indicated. Differences between groups were analyzed by student’s t-test if two groups were
analyzed or analysis of variance (ANOVA) if more than two groups were considered.
3. Results
3.1. µOR, but not δOR, activation affects cholangiocarcinoma cell proliferation, increasing
growth
Similarly to what observed in normal and hyperplastic cholangiocytes [7], malignant
cholangiocytes express both δOR and µOR (Fig. 1). In contrast, no expression neither of
δORnor of µOR was found in hepatocarcinoma cells (Alex-0 cells, Fig. 1).
Incubation of both HuH-28, Mz-ChA-1 and TFK-1 cells with DPDPE or DAMGO did not
modify cell proliferation when experiments were performed in 10% FBS medium (not shown).
In contrast, when cells were kept in FBS-free medium, increasing doses of DAMGO enhanced
cell proliferation in a dose-dependent fashion; no effects were instead elicited by DPDPE (Fig.
2A–C).
Increasing concentrations of DPDPE did not induce any change in PCNA protein expression
in HuH-28 cells (Fig. 2D), thus confirming that activation of δOR does not affect
cholangiocarcinoma cell proliferation.
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3.2. µOR signal in cholangiocarcinoma cells is mediated by ERK1/2, PI3K and Ca2+/
CamKIIα pathways
Incubation of HuH-28 cells with increasing concentrations of DAMGO dose-dependently
increased ERK1/2 and AKT phosphorylation (Fig. 3A), whereas no changes in PKA activity
were detectable in the same conditions (Fig. 3B).
When the Ca2+ signalling was studied, we found that DAMGO dose-dependently stimulated
CamKIIα phosphorrylation (Fig. 3C, left), whereas no changes were observed in PKCα
phosphorylation (Fig. 3C, right).
As a confirmation, the increase in HuH-28 cell proliferation induced by DAMGO was
neutralized by the pre-incubation with the MEK, PI3K and CamKII inhibitors or by the
intracellular Ca2+ chelator, but not by the pre-incubation with the PKA or Ca2+-dependent
PKC inhibitors (Fig. 4A).
DAMGO-induced increase in ERK1/2 phosphorylation was neutralized by the pre-incubation
with MEK inhibitor or with PI3K inhibitor, but not by the pre-incubation with PKA, CamKII
or Ca2+-dependent PKC inhibitors or with the intracellular Ca2+ chelator (Fig. 4B). In contrast,
DAMGO-induced increase in AKT phosphorylation was only prevented by the PI3K inhibitor
and not by any of the other inhibitors we tested (Fig. 4C).
3.3. µOR activation enhances cholangiocarcinoma cell migration
The presence of DAMGO enhanced cell migration, that resulted in increased rapidity in wound
closure: area included within the wound margins was found smaller both at 24 and at 72 h when
cells were incubated with DAMGO than in control (Fig. 5A). Similarly, DAMGO increased
migration rate when it was assessed by the specific cell migration assay (Fig. 5B).
3.4. µOR activation enhances cholangiocarcinoma cell survival in a PI3K-dependent manner
Exposure of HuH-28 cells to GCDCA resulted in a marked increase in caspase 3 activity
compared to control. When cells were pre-incubated with DAMGO, GCDCA-induced increase
in caspase 3 activity was significantly diminished (Fig. 6A). Such an effect was mediated by
the PI3K pathway, since the pre-incubation with wortmannin neutralised the DAMGO effects
on GCDCA-induced increase in caspase 3 activity (Fig. 6B). The blockage of the MAPK or
CamKII pathways (by PD98059 and KN62, respectively) did not affect the ability of DAMGO
to inhibit the GCDCA-induced increase in caspase 3 activity (Fig. 6B).
4. Discussion
The current study demonstrates that malignant cholangiocytes lose the response to the
inhibition of cell growth by endogenous opioid peptides, that is, in contrast, typical of
hyperplastic cholangiocytes [7]. Rather, our data indicate that human cholangiocarcinoma cells
respond with increased growth to the effect of endogenous opioid peptides. In particular, this
study shows that: (i) human cholangiocarcinoma cells express both δOR and µOR; (ii) human
cholangiocarcinoma cell growth cannot be inhibited by OR activation; µOR, but not δOR,
activation results in significant increase in cholangiocarcinoma cell proliferation; (iii) µOR
signal is mediated by ERK1/2, PI3K and Ca2+/CamKIIα pathways; (iv) µOR enhances
cholangiocarcinoma cell migration and escape from apoptosis.
Cholangiocarcinoma represents a challenge for clinicians, with most patients having an
advanced disease at the time of diagnosis [4].
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As for other malignancies, studies of the last 5–10 years demonstrated that what gives rise to
cholangiocarcinoma is the failure of the mechanisms that overviewcell proliferation, survival
and invasiveness [3]. What makes these mechanisms to fail remains an enigma.
Malignant transformation of cholangiocytes occurs in an environment characterized by chronic
inflammation and cholestasis [3]. Such a biological milieu is associated with increased
production of cytokines and molecules, like IL-6, hepatic growth factor (HGF),
cyclooxygenase (COX)-2, epidermal growth factor (EGF), that have been demonstrated to be
directly or indirectly responsible for promoting cholangiocarcinoma development [28–32].
Asecond major feature of chronic cholestasis is the release of a number of neuropeptides by
cholangiocytes; it is now thought that such a property of cholangiocytes allows them to
establish cell-to-cell interactions and most importantly to modulate their adaptive response to
cholestasis itself [6]. It is not known, however, if the failure of those mechanisms is associated
in any way to cholangiocarcinoma development.
It has been demonstrated that both human and experimental cholestasis is associated to the
synthesis by liver cells of endogenous opioid peptides [33–36]. Recently, it has been shown
that the biliary epithelium express OR [7,37], the activation of which aims to limit the
cholangiocyte hyperplastic proliferative response to cholestasis [7]. Endogenous opioid
peptides also play a significant role in the modulation of cancer cell growth, in particular of
gastrointestinal malignancies [8–10].
In the current study, we thus wanted to verify if cholangiocarcinoma development is associated
to the dysregulation of endogenous opioid peptides modulation of biliary cell growth.
In rodent non-malignant cholangiocytes, δOR and µOR activation results in opposite effects:
when δOR is stimulated, a marked inhibition of cholangiocyte proliferation is observed [7]. In
contrast, exposure to the µOR agonist only slightly increases cell growth [7]. In addition, in
in vivo models we demonstrated that the δOR inhibitory effect is the one that largely prevails
in pathophysiologic conditions [7]. Such effects are not species-specific, since OR activation
exerts similar effects on cell growth also when their activation is elicited in a human
cholangiocyte cell line (Marzioni et al., 2008, unpublished observations). In malignant
cholangiocytes δOR activation has no effects on cell growth, whereas µOR activation resulted
in a significant increase in cell proliferation (Fig. 2). These data indicate that malignant
cholangiocytes differ from hyperplastic (e.g. non-malignant) ones [7]: they lose the
susceptibility to the effect of the growth-inhibitor OR (e.g. δOR). Rather, and still in contrast
with non-malignant cholangiocytes [7], they display a marked response to growth-stimulator
OR (e.g. µOR). Altogether, our findings suggest the concept that, similarly to what happens
in other cells [38,39], the malignant transformation of cholangiocytes is associated with the
loss of their response to anti-proliferative factors and with the maintenance/amplification of
the response to pro-proliferative stimuli. If no expression of OR was found in hepatocarcinoma
cells (Fig. 1), the dysregulation of opioidergic modulation of cholangiocyte growth was evident
in all the three cell lines tested (Fig. 2). Therefore, these data indicate that: (i) locally released
endogenous opioid peptides are significant for biliary cancerogenesis independently from the
origin of the neoplasm along the biliary tract, since the same effects were evoked in
cholangiocarcinoma cells originated from intra- and extra-hepatic ducts and from gallbladder
[15–17]. To this regard, endogenous opioid peptides behaved similarly to other neuropeptides
[18,19,40,41]. (ii) The role of locally released endogenous opioid peptides is substantially
specific for biliary cancerogenesis, since hepatocarcinoma cells, as much as non-malignant
rodent and human hepatocytes [7], do not express OR.
We also found that the intracellular signalling is completely dysregulated in malignant
cholangiocytes when compared to hyperplastic ones [7]. In the latter, upon δOR stimulation,
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the activation of the Ca2+ signalling (Ca2+/CamKIIα/PKCα) results in a potent inhibition of
the PI3K/ERK1/2 cascade, with the consequent inhibition of cell growth [7]. In addition, µOR
stimulates cell growth through the PI3K/ERK1/2 cascade, but without affecting the Ca2+
signalling at all [7]. In contrast, in malignant cholangiocytes we found that µOR activates
Ca2+/CamKIIα cascade that elicits, instead of inhibiting, cell growth (Fig. 3B and A). These
data are in accordance with what previously observed in cholangiocarcinoma and other
malignancies: elevated levels of Ca2+-bound CamK are associated with cancer promotion,
invasiveness and immortalization [42–44]. These data, therefore, raise the interesting
hypothesis that the failure of the mechanisms that limit cholangiocyte proliferative response
to cholestasis (and the consequent development of biliary malignancies) may be ascribed to
the dysregulation of Ca2+/CamK signalling. The transition towards malignancy is also
associated to the complete loss of any role played by the cAMP/PKA pathway, that is a major
mediator of extracellular stimuli in non-malignant cholangiocytes [6]. It is needed to mention
that such changes in intracellular signals could be eventually ascribed to species-specific
differences between rodent hyperplastic cholangiocytes and human cholangiocarcinoma cells.
Despite that such an hypothesis cannot be completely ruled out, it is more likely that those
changes are due to the different biological state (hyperplastic vs. malignant): as mentioned
above, rodent and human cholangiocytes do not show any differences in terms of OR
expression [7] and biological response to OR activation.
In addition to uncontrolled cell proliferation, escape from apoptosis and enhanced invasiveness
are the other two major biological features of cholangiocarcinoma, that equally contribute to
its malignancy [3]. In this study we found that the exposure to the selective µOR agonist
accelerated HuH-28 cell migration, as resulted by both the wound-healing experiments and a
specific assay (Fig. 5A and B). Similarly, incubation with µOR agonist tended to reduce the
bile acid-induced activation of caspase 3 (Fig. 6A). Such an effect was mediated by the PI3K
pathway, since the pre-incubation with wortmannin neutralized the anti-apoptotic effect of
DAMGO (Fig. 6B). Our findings are thus in accordance with previous studies that showed
PI3K to be a major factor for cholangiocarcinoma cell survival [32,45–48]. To this extent, it
is accepted that cholangiocarcinoma does not differ from hepatocarcinoma [49–51] and other
malignancies [52].
Altogether, our findings are in agreement with the concept that changes in cholangiocarcinoma
cell proliferation are associated with parallel modifications of cell migration and opposite
tendency to cell death by apoptosis [18].
In conclusion, our study demonstrates for the first time that opioidergic modulation of
cholangiocyte biology is dysregulated in human cholangiocarcinoma cells, with a consequent
promotion of growth, survival and migration. This study thus confirm the hypotheses that had
been previously made by us and others [37,53]. Further studies are needed to clarify the actual
role of endogenous opioid peptides in human cases of cholangiocarcinogenesis. It can be
conceived that a genetic or acquired disruption of opioidergic regulation of cholangiocyte
biology may confer to a subset of patients a higher risk of developing such a malignancy. As
such and in perspective, the findings of the current study may thus open new scenarios for
novel surveillance or early diagnosis strategies for cholangiocarcinoma in the near future.
Practice points
• Malignant cholangiocytes are insensitive to the growth inhibition effect of δOR
activation.
• Malignant cholangiocytes only respond to the activation of µOR, that promotes
growth, survival and migration.
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• Such a dysregulation of OR regulation of cholangiocyte biology may be relevant
for cholangiocarcinoma development.
Research agenda
• To verify if a genetic or acquired disruption of opioidergic regulation of
cholangiocyte biology may confer to a subset of patients a higher risk of developing
cholangiocarcinoma.
• To verify if this information may contribute to develop novel strategies for
surveillance or early diagnosis of cholangiocarcinoma.
List of Abbreviations
cAMP, cyclic adenosine 3′,5′-monophosphate; PKA, protein kinase A; ERK, extracellular
regulated kinases; PI3K, phosphatidyl-inositol-3-kinase; OR, opioid receptor; BrDU, bromod-
eoxyuridine; GCDCA, glycochenodeoxycholic acid.
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Fig. 1.
Evaluation of OR expression in cells of three different cholangiocarcinoma cell lines (Mz-
ChA-1, TFK-1 and HuH-28) and in a hepatocarcinoma cell line (Alex-0 cells), assessed by
immunoblotting. The cells of the three cholangiocarcinoma cell lines express both δOR and
µOR, whereas no expression was found in hepatocarcinoma cells.
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Fig. 2.
Effect of OR activation on human cholangiocarcinoma cell proliferation cultured in FBS-free
medium, measured by BrDU incorporation (A–C). Increasing doses of µOR (DAMGO), but
not of δOR (DPDPE), selective agonist markedly increased HuH-28 (A), Mz-ChA-1 (B) and
TFK-1 (C) cholangiocarcinoma cell proliferation. Data are expressed as mean ± S.E. of three
experiments. *p < 0.05 vs. basal. (D) Effect of δOR activation on HuH-28 cell proliferation
assessed by PCNA protein expression. Increasing concentrations of DPDPE did not determine
changes in PCNA protein expression, neither in cells cultured in the presence (left) nor in the
absence (right) of 10% FBS-enriched medium. Data are expressed as mean ± S.E. of three
experiments. *p ≤ 0.05 vs. basal.
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Fig. 3.
Effect of µOR activation on intracellular signalling in HuH-28 cells. (A) Incubation with
increasing doses of DAMGO corresponded to a dose-dependent increase of ERK1/2 (left) and
AKT (right) phosphorylation. Data are expressed as mean ± S.E. of three experiments. #p <
0.05 vs. pERK1 basal value; *p < 0.05 vs. pERK2 basal value; ◦p < 0.05 vs. pAKT basal value.
(B) Incubation with increasing doses of DAMGO did not induce significant changes in PKA
activity (left); active PKA provided by the vendor and cholangiocytes isolated from rats
subjected to 1 week BDL were taken as positive controls (right, representative image). Data
are expressed as mean ± S.E. of three experiments. (C) µOR activation corresponded to a dose-
dependent increase of CamKIIα (left) but not PKCα (right) phosphorylation. Data are expressed
as mean ± S.E. of three experiments. §p < 0.05 vs. pCamKIIα basal value.
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Fig. 4.
(A) The DAMGO-induced increase in HuH-28 cell proliferation was neutralised by the pre-
incubation with PI3K (wortmannin), MEK (PD98059) and CamKII (KN62) inhibitors and with
the intracellular Ca2+ chelator (BAPTA/AM). In contrast, DAMGO-induced increase in cell
proliferation was not affected by the pre-incubation with the cAMP-dependent PKA inhibitor
(Rp-cAMPs) or the Ca2+-dependent PKC inhibitor (Ro-32-0432). Data are expressed as mean
± S.E. of three experiments. *p < 0.05 vs. the other groups. (B) Only PI3K and MEK inhibitors
blocked the DAMGO-induced increase in ERK1/2 phosphorylation, whereas no effect was
observed after the pre-incubation with the other inhibitors. Data are expressed as mean ± S.E.
of three experiments. #p < 0.05 vs. pERK1 value of the other groups; §p < 0.05 vs. pERK2
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value of the other groups. (C) DAMGO-induced increase in AKT phosphorylation was
neutralised only by the PI3K inhibitor wortmannin. Data are expressed as mean ± S.E. of three
experiments. ◦p < 0.05 vs. the other groups.
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Fig. 5.
Effect of µOR activation on HuH-28 cell migration and survival. (A) Wound-healing
experiments showed that µOR activation markedly diminished both after 24 and 72 h, the area
included within the wound margins (outlined by the red-scattered line). Data are expressed as
mean ± S.E. of three experiments. *p < 0.05 vs. the corresponding basal value. (B) Cell
migration assay demonstrated that the µOR selective agonist DAMGO markedly enhanced
HuH-28 cell migration; cells cultured in 10% FBS enriched medium were used as positive
control. Data are expressed as mean ± S.E. of three experiments. ◦p < 0.05 vs. basal.
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Fig. 6.
(A) Incubation of HuH-28 cells with GCDCA resulted in marked activation of caspase 3; such
effect was reduced when cells were pre-incubated with DAMGO. Data are expressed as mean
± S.E. of three experiments. #p < 0.05 vs. basal; §p < 0.05 vs. GCDCA+DAMGO. (B) Only
the pre-incubation with wortmannin neutralised the effects of DAMGO on GCDCA-induced
increase in caspase 3 activity assay. No effects were seen when cells were pre-incubated with
PD98059 or KN62. Data are expressed as mean ± S.E. of three experiments. *p < 0.05 vs. the
other groups.
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